FEB 1.6 LIVE STATES PATENT AND TRADEMARK OFFICE

In re application of:) Examiner: Walicka, Malgorzata A.
Philip J. BARR, et al.) Group Art Unit: 1652
Application Serial No. 10/025,514) Confirmation No: 6421
Filed: December 18, 2001) Attorney's Docket No. 39042-0008
For: MULTIFUNCTIONAL PROTEASE INHIBITORS AND THEIR USE IN TREATMENT OF DISEASE) Customer No. 25213))

VIA EXPRESS MAIL EV 766 020 720 US DATE FILED: February 16, 2007

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609. The items labeled with * were cited during prosecution of the corresponding European patent application.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

\boxtimes	This statement	qualifies	s under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
		(1) than a	It is being filed within 3 months of the application filing date and is other continued prosecution application under § 1.53(d) OR
		(2)	It is being filed within 3 months of entry of a national stage OR
		(3) merits	It is being filed before the mail date of the first Office Action on the



OIPE WAS	
FEB 16 2001 B	\boxtimes
TRAVERSE	37 C.F.R. §

It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

 $\S1.97(c)$. If this statement is being filed after the latest of: (1) three months beyond the of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

a certification as specified in §1.9/(e) is provided below; or
a fee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included with
the payment of other papers filed together with this statement.

- 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
 - A. . a certification as specified in §1.97(e) is completed below; and
 - B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and
 - C. a fee of \$180.00 as set forth in \$1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- \boxtimes Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Attorney's Docket No. 39042-0008).

Respectfully submitted,

Dated: February 16, 2007

Leslie Mooi (Reg. No./37,047)

HELLER EHRMAN LLP

275 Middlefield Road Menlo Park, California 94025-3506

Telephone: (650) 324-7000 Facsimile: (650) 324-0638

PE 40 STATEMENT PTO-1449			ATTY. DOCKET NO.: 39042-0008 10/025,514 APPLICANT: Philip J. BARR, et al. FILING DATE: December 18, 2001 GROUP: 1652				
THAT THAT THAT THE THAT	<u>/</u>		U.S. PATENT DOCUMENT				
EXAMINER'S INITIALS	PATENT NO. OR PUBLICATION NO.	DATE	NAME	CLASS	SUBCLASS	FILI	NG DATE
						<u> </u>	
							
	· · · · · · · · · · · · · · · · · · ·		REIGN PATENT DOCUMEN		T	T	NGL 4 TION
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	WO 92/10575	06/25/1992	PCT				
	OTHER	DOCUMENT	S (Including Author, Title, Day	te, Pertinent	Pages, Etc.)	I	
			gineering, Vol. 11, No. 12, pages				· .
	Brantly, M.L. et al., Chest, Vol. 100, No. 3, pages 703-708 (1991).						
	Chughtai, B. et al., Journal of Aerosol Medicine, Vol. 17, No. 4, pages 289-298 (2004).						
	Cox, D.W. et al., Hum. Genet., Vol. 61, No. 2, pages 123-126 (1982).						
-	Curiel, D. et al., Am. J. Respir. Cell Mol. Biol., Vol. 1, No. 6, pages 471-477 (1989).						
	Djie, M.Z. et al., The Journal of Biological Chemistry, Vol. 272, No. 26, pages 16268-16273 (1997).						
	Dobó, J. et al., The Journal of Biological Chemistry, Vol. 279, No. 10, pages 9264-9269 (2004).						
	Dykes, D.D. et al., Crit. Rev. Clin. Lab Sci., Vol. 20, No. 2, pages 115-151 (1984).						
	Dykes, D.D. et al., Hum. Hered, Vol. 34, No. 5, pages 308-310, (1984).						
*	Eisenberg, S. P. et al., The Journal of Biological Chemistry, American Society of Biolochemical Biologists, Vol. 265, No. 14, pages 7976-7981 (1990).						
	Faber, J.P. et al., A	m. J. Hum. Ge	net., Vol. 55, No. 6, pages 1113-	-1121 (1994).			
	Gahne, B. et al., Anim. Genet., Vol. 17, No. 2, pages 135-157 (1986).						
	Gaillard, I. et al., DNA, Vol. 8, No. 2, pages 87-99 (1989).						
	Goodwin, R.L. et al., Mol. Biol. Evol., Vol. 13, No. 2, pages 346-358 (1996).						
	Hopkins, P.C.R. et al., The Journal of Biological Chemistry, Vol. 270, No. 20, pages 11866-11871 (1995).						
	Im, H. et al., Protein Science, Vol. 9, pages 1497-1502 (2000).						
	Im, H. et al., The Journal of Biological Chemistry, Vol. 277, No. 48, pages 46347-46354 (2002).						
EVANDED	DATE CONSIDERED						

INFOR	MATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO.: 39042-0008	SERIAL NO.: 10/025,514			
EEB 1.8 5001 P		APPLICANT: Philip J. BARR, et al. FILING DATE: December 18, 2001 GROUP: 1652				
	Jeppsson J.O. et al., J. Chromatog	atogr., Vol. 26, No. 327, pages 173-177 (1985).				
A TRADE	Kelley, R.F. et al., Blood, Vol. 89, No. 9, pages 3219-3227 (1997).					
	Lukacs, C.M. et al., Biochemistry, Vol. 37, No. 10, pages 3297-3304 (1998).					
	Marshall, C.J., Philos Trans. R. Soc. Lond. B. Biol. Sci., Vol. 342, No. 1300, pages 101-119 (1993). Martin, D.M.A. et al., The Faseb Journal, Vol. 9, pages 852-859 (1995).					
-	Okayama, H. et al. Am. J. Hum. Genet., Vol. 48, No. 6, pages 1154-1158 (1991).					
-	Okayama, H. et al. Biochem. Biophys. Res. Commun., Vol. 162, No. 3, pages 1560-1570 (1989).					
	Plotnick, M.I. et al., The Journal of Biological Chemistry, Vol. 277, No. 33, pages 29927-29935 (2002).					
	Rudolphus, A., Histochemical Journal, Vol. 26, pages 817-824 (1994).					
	Salahuddin, P., Indian J. Biochem. Biophys, Vol. 28, No. 3, pages 164-167 (1991). Schick, C. et al., Proc. Natl. Acad. Sci. USA, Vol. 95, pages 13465-13470 (1998).					
	Schulze, A.J., Eur. J. Biochem., Vol 202, No. 3, pages 1147-1155 (1991).					
	Sesboue R. et al., Hum. Hered, Vol. 34, No. 2, pages 105-113 (1984).					
	Silverman, G.A. et al., The Journal of Biological Chemistry, Vol. 276, No. 36, pages 33293-33296 (2001).					
	Stetler, G. et al., Nucleic Acids Research, Vol. 14, No. 20, pages 7883-7896 (1986). Tanaka, T. et al., The Journal of Biological Chemistry, Vol. 259, No. 13, pages 8063-8065 (1984).					
*	Wolfson A. J. et al., Protein and Peptide Letters, Vol. 3, No. 5, pages 293-300 (1996).					
	Wright, C.D., The Journal of Pharmacology and Experimental Therapeutics, Vol. 289, No. 2, pages 1007-1014 (1999).					
	Xue, Y. et al., Structure, Vol. 6, No. 5, pages 627-636 (1998).					
	Yamasaki, M. et al., The Journal of Biological Chemistry, Vol. 278, No. 37, pages 35524-35530 (2003).					
	Yuasa, I. et al., Hum. Genet, Vol. 67, No. 2, pages 209-212 (1984).					
	Zhou, A. et al., The Journal of Biological Chemistry, Vol. 276, No. 29, pages 27541-27547 (2001).					
EXAMINER		DATE CONSIDERED				